Abstract
Alzheimer’s disease (AD) is an irreversible multifaceted neurodegenerative disorder that gradually degrades neuronal cells. Presently, it is the most common reason for the memory loss and dementia in older individuals. It is patho-physiologically described by extracellular amyloid beta (Aβ) deposition, intracellular neurofibrillary tangles (NFTs) retention, neuronal decline, and neurotransmitter system derangement. Various receptors such as nicotinic acetylcholine, N-methyl-D-aspartate, insulin, serotonin, adenosine, and histamine are actively involved in the physiological progression of AD. Till date memantine and only four other acetylcholinesterase inhibitors have been approved for the treatment of AD by US Food and Drug Administration (US-FDA). Hence, there is a critical need to explore and develop novel and helpful management systems which could specifically target different receptors involved in AD progression. We believe that these receptors targeting will either impede the disease onset or slow down its pathogenesis. In the present review, we tried to uncover some receptors that could be blocked by novel inhibitors and ultimately used for the therapeutic management of AD.
Keywords: Alzheimer's disease, Nicotinic acetylcholine receptors, N-methyl-D-aspartate receptor, Insulin receptor, Adenosine receptor.
Current Topics in Medicinal Chemistry
Title:Elucidating Treatment of Alzheimer's Disease via Different Receptors
Volume: 17 Issue: 12
Author(s): Badar ul Islam, Mohd Shahnawaz Khan, Nasimudeen R. Jabir, Mohammad Amjad Kamal and Shams Tabrez
Affiliation:
Keywords: Alzheimer's disease, Nicotinic acetylcholine receptors, N-methyl-D-aspartate receptor, Insulin receptor, Adenosine receptor.
Abstract: Alzheimer’s disease (AD) is an irreversible multifaceted neurodegenerative disorder that gradually degrades neuronal cells. Presently, it is the most common reason for the memory loss and dementia in older individuals. It is patho-physiologically described by extracellular amyloid beta (Aβ) deposition, intracellular neurofibrillary tangles (NFTs) retention, neuronal decline, and neurotransmitter system derangement. Various receptors such as nicotinic acetylcholine, N-methyl-D-aspartate, insulin, serotonin, adenosine, and histamine are actively involved in the physiological progression of AD. Till date memantine and only four other acetylcholinesterase inhibitors have been approved for the treatment of AD by US Food and Drug Administration (US-FDA). Hence, there is a critical need to explore and develop novel and helpful management systems which could specifically target different receptors involved in AD progression. We believe that these receptors targeting will either impede the disease onset or slow down its pathogenesis. In the present review, we tried to uncover some receptors that could be blocked by novel inhibitors and ultimately used for the therapeutic management of AD.
Export Options
About this article
Cite this article as:
ul Islam Badar, Khan Shahnawaz Mohd, Jabir R. Nasimudeen, Kamal Amjad Mohammad and Tabrez Shams, Elucidating Treatment of Alzheimer's Disease via Different Receptors, Current Topics in Medicinal Chemistry 2017; 17 (12) . https://dx.doi.org/10.2174/1568026617666170103163715
DOI https://dx.doi.org/10.2174/1568026617666170103163715 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Heterocyclic Secretase Inhibitors for the Treatment of Alzheimer’s Disease: An Overview
Central Nervous System Agents in Medicinal Chemistry Effects of Folic Acid and Vitamin B12, Alone and in Combination on Cognitive Function and Inflammatory Factors in the Elderly with Mild Cognitive Impairment: A Single-blind Experimental Design
Current Alzheimer Research Subject Index To Volume 2
Current Rheumatology Reviews An fMRI Stroop Task Study of Prefrontal Cortical Function in Normal Aging, Mild Cognitive Impairment, and Alzheimers Disease
Current Alzheimer Research Evidence for the Role of Luteinizing Hormone in Alzheimer Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets The Role of Apoptotic Pathways in Alzheimers Disease Neurodegeneration and Cell Death
Current Alzheimer Research Serum Fragments of Tau for the Differential Diagnosis of Alzheimer's Disease
Current Alzheimer Research Interindividual Variability in the Efficacy of Oral Antiplatelet Drugs: Definitions, Mechanisms and Clinical Importance
Current Pharmaceutical Design Long-term Potentiation at Spinal C-fiber Synapses: A Target for Pathological Pain
Current Pharmaceutical Design Change in INSR, APBA2 and IDE Gene Expressions in Brains of Alzheimer's Disease Patients
Current Alzheimer Research Coumarins as Promising Scaffold for the Treatment of Age-related Diseases – An Overview of the Last Five Years
Current Topics in Medicinal Chemistry Demystifying the ACE Polymorphism: From Genetics to Biology
Current Pharmaceutical Design Changes in Speech Chunking in Reading Aloud is a Marker of Mild Cognitive Impairment and Mild-to-Moderate Alzheimer’s Disease
Current Alzheimer Research Peptides and their Metal Complexes in Neurodegenerative Diseases: from Structural Studies to Nanomedicine Prospects
Current Medicinal Chemistry Inhibition of β-Amyloid Aggregation by Albiflorin, Aloeemodin and Neohesperidin and their Neuroprotective Effect on Primary Hippocampal Cells Against β-Amyloid Induced Toxicity
Current Alzheimer Research Peroxisome Proliferator-Activated Receptor (PPAR) in Metabolic Syndrome and Type 2 Diabetes Mellitus
Current Diabetes Reviews Alzhemed: A Potential Treatment for Alzheimers Disease
Current Alzheimer Research The Extra-Hematopoietic Role of Erythropoietin in Diabetes Mellitus
Current Diabetes Reviews Phosphodiesterase Inhibitors for Cognitive Enhancement
Current Pharmaceutical Design Design and Development of Resveratrol NLCs and their Role in Synaptic Transmission of Acetylcholine in C. elegans Model
Current Drug Therapy